Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
Wathikthinnakon M, Luangwattananun P, Sawasdee N, Chiawpanit C, Lee VS, Nimmanpipug P, Tragoolpua Y, Rotarayanont S, Sangsuwannukul T, Phanthaphol N, Wutti-In Y, Somboonpatarakun C, Chieochansin T, Junking M, Sujjitjoon J, Yenchitsomanus PT, Panya A. Wathikthinnakon M, et al. Among authors: sangsuwannukul t. Sci Rep. 2022 Apr 13;12(1):6154. doi: 10.1038/s41598-022-09964-6. Sci Rep. 2022. PMID: 35418130 Free PMC article.
Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P, Sangsuwannukul T, Supimon K, Thuwajit C, Chieochansin T, Sa-Nguanraksa D, Samarnthai N, O-Charoenrat P, Junking M, Yenchitsomanus PT. Luangwattananun P, et al. Among authors: sangsuwannukul t. Int Immunopharmacol. 2023 Nov;124(Pt B):111012. doi: 10.1016/j.intimp.2023.111012. Epub 2023 Oct 5. Int Immunopharmacol. 2023. PMID: 37804657
Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach.
Rujirachaivej P, Siriboonpiputtana T, Choomee K, Supimon K, Sangsuwannukul T, Songprakhon P, Natungnuy K, Luangwattananun P, Yuti P, Junking M, Yenchitsomanus PT. Rujirachaivej P, et al. Among authors: sangsuwannukul t. J Transl Med. 2025 Jan 13;23(1):54. doi: 10.1186/s12967-024-05923-z. J Transl Med. 2025. PMID: 39806405 Free PMC article.
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.
Vile R, Pulido J, Chen A, Kendall B, Tonne J, Metko M, Thompson J, Sangsuwannukul T, Yerovi MC, Diaz R, Webb M, Huff A, Moore M, Schuelke M, Irshad S, Appleton E, Melcher A. Vile R, et al. Among authors: sangsuwannukul t. Res Sq [Preprint]. 2024 Nov 15:rs.3.rs-5411393. doi: 10.21203/rs.3.rs-5411393/v1. Res Sq. 2024. PMID: 39606441 Free PMC article. Preprint.
12 results